Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arizona for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arizona only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arizona (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Mona Amin (NPI 1740476217)

Field	Value
Entity Type	Individual
Organization	Mona Amin
Address	5681 W Beverly Ln Ste 100
City	Glendale
State	AZ
ZIP	85306
Taxonomy	Rheumatology Physician
NPI Enumerated	September 19, 2007

Payer Source	Total Paid
Medicare	$2.7M
Medicaid	$0

Key Findings

This provider’s billing footprint is concentrated in Medicare: lifetime Medicare revenue is $2.7M and there is no Medicaid billing on file, so the practice is effectively single‑payer with all measurable public-payor volume coming from Medicare. That concentration creates operational dependence on Medicare fee schedules and beneficiary referrals rather than on state Medicaid contracts.

Revenue is highly concentrated in a small set of biologic drug codes: the precomputed top three codes account for 52.3% of Medicare revenue, driven by J0897 ($565.9K, 20.8% of Medicare revenue), J3262 ($450.8K, 16.6%), and J0129 ($404.6K, 14.9%). This concentration indicates a business model where high-cost injectable biologics are the primary revenue drivers.

The code mix points to a rheumatology practice that administers parenteral biologic therapies and provides infusion/clinic-based drug administration rather than relying solely on office evaluation visits. Prominent biologic and infusion codes include J0897, J3262, J0129, J1602, J3111 and J1745, complemented by chemotherapy/infusion administration codes such as 96413 and 96401, consistent with in-office infusion services and biologic management.

On competitive standing, J0897 is an extreme national outlier: the provider ranks #89 of 10057 (99th percentile; extreme outlier), indicating far higher-than-typical national volume for that specific drug. By contrast J3262 (rank #68 of 618, 89th percentile; typical, unremarkable volume) and J0129 (rank #375 of 1221, 69th percentile; typical, unremarkable volume) show above-average but more conventional participation in their peer groups, so the provider’s national dominance is concentrated on a single drug code rather than across all biologics.

Clinical throughput appears substantial for established patients: 99214 totals 1.1K claims with $103K revenue (3.8% of Medicare revenue) and the provider ranks #8097 of 479517 (98th percentile; extreme outlier) for that code. This combination of high E/M volume for established visits plus significant biologic administration suggests a sizable, ongoing patient panel managed in clinic.

Infusion and supportive administration services are meaningfully represented: 96413 (687 claims, $66.6K, 2.5% of Medicare revenue) ranks #281 of 7514 (96th percentile; notably above typical), and 96401 (909 claims, $47.3K, 1.7% of Medicare revenue) ranks #88 of 3868 (98th percentile; notably above typical). These high percentiles for infusion administration codes further support that the practice operates an in‑office infusion/administration capability rather than only prescribing biologics for external administration.

Laboratory and bone-health monitoring codes are reported at high relative volume for peers, consistent with active rheumatologic disease management: 82306 (vitamin D) is 543 claims, $15.7K revenue and ranks in the 95th percentile; 86140 (CRP) is 1K claims, $5.1K and ranks in the 94th percentile; and 77085 (bone density) appears with 104 claims and $5.3K revenue (78th percentile). Together these diagnostics indicate routine monitoring of inflammatory markers and bone health as part of longitudinal care.

The provider has a long tenure: NPI enumerated 2007-09-19 (~19 years ago), which aligns with an established practice pattern and supports the interpretation that high biologic and infusion volumes reflect stable, ongoing clinical services rather than a recent change in practice mix. Given the lack of Medicaid billing, this tenure combined with Medicare concentration suggests an experienced clinician with an established Medicare patient base and in‑office biologic/infusion services.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

64 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0897	Injection, denosumab, 1 mg	31,440	$20	$565.9K
J3262	Injection, tocilizumab, 1 mg	90,150	$10	$450.8K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	11,900	$30	$404.6K
J1602	Injection, golimumab, 1 mg, for intravenous use	32,970	$10	$362.7K
J3111	Injection, romosozumab-aqqg, 1 mg	44,310	$10	$354.5K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	36,400	$1	$145.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,140	$90	$103K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	3,160	$30	$82.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	690	$100	$66.6K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	910	$50	$47.3K

Showing 1–10 of 64

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 64 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arizona Distribution

Mona Amin — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arizona

Full comparison — all codes billed, vs. state median

64 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	21	30	14,700	$30	$494.5K
J3262	7	20	74,500	$1	$367.2K
J1602	10	30	24,040	$10	$316.2K
J0717	10	20	36,100	$1	$246.6K
J3111	6	40	19,530	$10	$178.8K
J0897	10	260	2,940	$20	$115.6K
J1745	16	40	2,980	$30	$103.9K
86235	17	20	130	$20	$59.5K
83970	88	130	80	$40	$33K
86480	15	20	110	$60	$27.2K

Showing 1–10 of 64

Related Providers

Other providers that share a Tax Identification Number (TIN) with Mona Amin, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Arizona Arthritis & Rheumatology Associates P C	AZ	Rheumatology Physician	$0	$11.2M
Nehad Soloman	AZ	Rheumatology Physician	$5.1M	$0
Alexander Hu	AZ	Internal Medicine Physician	$3.8M	$0
Areena Swarup	AZ	Rheumatology Physician	$3.6M	$0
Saima Chohan	AZ	Rheumatology Physician	$3.5M	$0
Ravi Bhalla	AZ	Rheumatology Physician	$2.8M	$435.8K
Nikila Kumar	AZ	Rheumatology Physician	$3M	$0
John Tesser	AZ	Rheumatology Physician	$3M	$0
Daniel Kreutz	AZ	Rheumatology Physician	$2.8M	$0
Joonhee Lim	AZ	Rheumatology Physician	$2.3M	$0

Nearby Providers

Other providers in the same ZIP code as Mona Amin, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Banner Thunderbird Medical Center	AZ	General Acute Care Hospital	$0	$140.1M
North Valley Emergency Specialists	AZ	Emergency Medicine Physician	$0	$23.2M
Emeritus Properties Ngh, LLC	AZ	Assisted Living Facility	$0	$12.1M
Satinder S. Purewal, M.d. LLC	AZ	Psychiatry Physician	$0	$9.4M
Founders Healthcare, LLC	AZ	Durable Medical Equipment & Medical Supplies	$0	$8.9M
Jewish Family & Children's Service	AZ	Community/Behavioral Health Agency	$0	$7.5M
Children's Medical Group, Ltd	AZ	Pediatrics Physician	$0	$7.5M
Andrew Sharobeem	AZ	Rheumatology Physician	$2.3M	$0
Adam Leon	AZ	Nurse Practitioner	$2M	$0
Murali Murty	AZ	Radiation Oncology Physician	$1.3M	$0

Mona Amin — Billing Profile & Reimbursement Data

Sign up for Mona Amin — Billing Profile & Reimbursement Data policy alerts

Mona Amin — Billing Profile & Reimbursement Data

Sign up for Mona Amin — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References